Activity Number and Title
19CE096 - Understanding Hemophilia
Purpose Statement
"Understanding Hemophilia" is a 6-part online learning activity that aims to enable clinicians at U.S. Hemophilia Treatment Centers to gain knowledge and develop expertise on the pathogenesis, inheritance, symptoms, potential complications, and clinical management of hemophilia.
Educational Objectives
- Describe the pathogenesis and inheritance patterns concerning the different factor deficiencies in hemophilia including the symptoms and sequelae that may occur
- Discuss the target factor levels for situational bleeding episodes in conjunction with the appropriate factor replacement protocols, prophylactic treatments, and nursing considerations in administration of clotting factor concentrates
- Review the development and impact of inhibitors on persons with hemophilia, including signs and symptoms, risk factors, treatment implications, and nursing considerations
- Summarize the MASAC recommendations on the use of Emicizumab such as the indications, management approaches, and concurrent use with bypassing agents
- Articulate the role of genetic testing in the identification of potential carriers and women with hemophilia and the hemostatic management recommendations during pregnancy, labor and delivery, and the postpartum phases
Target Audience
This online learning activity is intended for nurses, nurse practitioners, physician assistants, and other clinical staff within the federally recognized U.S. Hemophilia Treatment Center (HTC) network who wish to develop an understanding of basic concepts of hemophilia. The activity is particularly appropriate for clinicians within their first six months of employment at an HTC.
Topics/Content
This 6-part online learning activity introduces basic concepts of hemophilia.
Part 1: Pathogenesis & Inheritance examines the coagulation system and processes, the deficit in hemophilia that interferes with clot formation, differences among types of hemophilia, and the sex-linked inheritance pattern of hemophilia.
Part 2: Symptoms & Sequelae distinguishes bleeding patterns and clinical presentation of hemophilia based on severity, differentiates types of bleeding episodes, and discusses physical/psychosocial sequelae of hemophilia.
Part 3: Factor Concentrates & Hemophilia Management discusses episodic and prophylactic management of hemophilia with clotting factor concentrate, different factor therapy protocols, and nursing considerations in administration of clotting factor concentrates.
Part 4: Introduction to Inhibitors explains the immune response and inhibitor development, signs/symptoms and risk factors of inhibitors, the impact of inhibitors on persons with hemophilia, inhibitor treatment strategies and challenges, and the positive health outcomes of immune tolerance induction therapy.
Part 5: Emicizumab covers the novel agent emicizumab, including its indications, mechanism of action, dosing options, lab considerations; as well as management of breakthrough bleeding, the boxed warning of emicizumab, use of emicizumab concurrently with bypassing agents, and potential considerations in the management of persons with hemophilia with or without inhibitors who utilize emicizumab.
Part 6: Carrier Considerations reviews hemophilia sex-linked genetics and introduces recommendations for the management of carriers and women with hemophilia, neonatal diagnosis and circumcision in males with hemophilia, and key considerations of postpartum management of carriers and women with hemophilia.
Faculty w/ credentials
- Jennifer Maahs, MSN, PNP, RN-BC
- Amy Shapiro, MD
Date of Original Release
February 7, 2020
Expiration Date
5:00 PM Eastern, February 7, 2022
Method of Participation
The estimated time to complete this activity is 120 minutes. In order to receive contact hours, you must complete the following prior to the course expiration date:
- Read the Program Announcement Form
- Complete the learning activity
- Complete the evaluation
- Complete the post-test with a score of 80% or better.
- Upon successful completion of the post-test your certificate of completion will be available to print or save
Accreditation Statement and Contact Hours
The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Centers Commission on Accreditation.
This activity is provided for 2.0 contact hours under ANCC criteria.
This activity is provided for 0.3 contact hours related to pharmacotherapeutic content.
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 2 AAPA Category 1 CME credits. Approval is valid from 2/7/2021 to 2/7/2022. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-201887.
Contact Information
System Requirements
- 2 gigabytes of RAM
- High speed internet connection
- Any one Internet browser:
- Firefox (Most Current Version)
- Safari (Most Current Version)
- Google Chrome (Most Current Version)
- MS Internet Explorer (Most Current Version)
- Cookies and JavaScript must be enabled in all browsers.
- All browsers must have flash plug in installed and enabled.
- Cookies and JavaScript must be enabled in all browsers.
- All browsers must have flash plug in installed and enabled.
